Bruno Sangro
布鲁诺·桑格罗
MD, PhD
Professor of Medicine, Director of Liver Unit医学教授，肝脏科主任
👥Biography 个人简介
Leading European HCC specialist integrating locoregional and systemic therapies. Contributed to validation of TACE and radioembolization (SIRT) and pioneered early pembrolizumab HCC trials (KEYNOTE-240). Author of major ESMO and EASL HCC guidelines shaping global liver cancer management.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
HCC Locoregional Therapy
Contributed pivotal work on TACE and Y-90 SIRT radioembolization, establishing evidence base for locoregional treatment algorithms in intermediate-stage HCC.
Immunotherapy in HCC
Key investigator in KEYNOTE-240 trial of pembrolizumab in previously treated HCC, advancing checkpoint inhibitor use in liver cancer.
Representative Works 代表性著作
Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma (KEYNOTE-240)
Journal of Clinical Oncology (2020)
Phase III trial evaluating pembrolizumab in advanced HCC after sorafenib progression.
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Journal of Hepatology (2022)
Comprehensive updated EASL HCC guidelines co-authored, directing global liver cancer care.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 布鲁诺·桑格罗 的研究动态
Follow Bruno Sangro's research updates
留下邮箱，当我们发布与 Bruno Sangro（Clínica Universidad de Navarra）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment